NextCure's LNCB74 dose-escalation update tests a B7-H4 ADC facing GSK, AstraZeneca
NextCure plans a Phase 1 update on its B7-H4-targeted ADC LNCB74 in the second half of 2026, in a field where GSK and AstraZeneca already have Phase 3 B7-H4 ADCs running.
Executive Summary
- NextCure is preparing to share new data from the dose-escalation phase of its B7-H4-directed antibody-drug conjugate, a study still finding its recommended dose rather than testing for efficacy.
- The update lands in a B7-H4 field where larger rivals have already moved into Phase 3 testing, which raises the bar for what an early dose-escalation signal needs to show to matter.
- The trial has progressed on schedule, with enrollment steady at its planned level and higher-dose cohorts now enrolling, meaning the story is about what the data show, not whether the trial is running into trouble.
- A tolerable higher-dose cohort with a defined recommended Phase 2 dose would let NextCure advance LNCB74 toward expansion cohorts, while safety findings at the top doses would test the differentiation case for its linker and payload design.
The catalyst
NextCure said it plans to provide a trial update on the ongoing Phase 1 dose-escalation study of LNCB74 (NCT06774963) in the second half of 2026, a window it first guided to in a March 5, 2026 business update and reaffirmed in its first-quarter 2026 report. The study is testing LNCB74, an antibody-drug conjugate directed at B7-H4 that pairs a tumor-selective cleavable linker with the tubulin inhibitor MMAE, in adults with advanced, unresectable or metastatic tumors who have measurable disease by RECIST 1.1. The trial's two primary endpoints are defining a recommended Phase 2 dose and evaluating safety and tolerability, the standard aims of a dose-escalation study rather than a proof-of-efficacy test. NextCure+1NextCure Provides Business Update and Reports Full Year 2025 Financial ResultsMar 5, 2026A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Where the trial stands
The study has enrolled toward an anticipated total of 145 patients since opening in January 2025, with a primary completion date of December 1, 2026 that falls inside the company's guided disclosure window. NextCure said higher-dose cohort enrollment began following a protocol amendment announced in November 2025, with the next cohort prioritizing patients with high B7-H4 expression in breast and gynecological cancers and adding adenoid cystic carcinoma type 1. The trial has logged a single registry change event since its initial posting and carries a stable protocol-stability label, and its enrollment target has not moved from its original 145, both consistent with routine Phase 1 progression rather than any operational strain. NCT06774963+1A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963NextCure Provides Business Update and Reports Full Year 2025 Financial ResultsMar 5, 2026
The competitive bar
B7-H4 is not an open field. GlaxoSmithKline's GSK5733584 has already reached Phase 3 testing in ovarian and endometrial cancer, and AstraZeneca's puxitatug samrotecan is in a Phase 3 trial comparing it against chemotherapy in B7-H4-selected endometrial cancer. Hansoh BioMedical's HS-20089 and Mersana Therapeutics' XMT-1660 are both in earlier-phase B7-H4 ADC testing, with XMT-1660's own Phase 1 dose-escalation study nearing a December 2026 completion. Against that backdrop, LNCB74 remains the only Phase 1 asset pairing the B7-H4 target with advanced tumors as its indication, and no B7-H4 x -tumor trial in this landscape has been terminated to date, though the sample of resolved trials remains small. A dose-escalation update that defines a tolerable recommended Phase 2 dose with response signal in high B7-H4-expressing tumors would be the result that lets LNCB74 credibly enter a field where two mechanistically similar ADCs are already three phases ahead.
The sponsor picture
NextCure has completed one of four prior industry trials and terminated three, a small sample that limits any read on execution history. The company is running LNCB74 alongside its licensed CDH6-targeted ADC SIM0505, for which it reported Phase 1 dose-escalation data and started a dose-optimization study in ovarian cancer earlier in 2026, giving the company an active dual-ADC dose-escalation cadence across two separate targets this year. NextCureNextCure Provides Business Update and Reports Full Year 2025 Financial ResultsMar 5, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.